BNC Purpose Canadian Financial Income Fund

-NexHA(TM )to be available for sale in coming months- BELLEVILLE, ON, Oct. 27, 2011 /CNW/ - Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has received a notice of compliance from Health Canada's Veterinary Drugs Directorate for a low molecular weight hyaluronate sodium product for horses that the Company expects to launch in the next several months. The new product, NexHA(TM), is a specialized formulation of purified hyaluronate sodium that can be administered to horses by intravenous or intra-articular injection. It is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis. Hyaluronate sodium acts as a replacement for synovial fluid, the naturally occurring lubricant in articular joints. Joint degeneration is associated with the loss of synovial fluid, and the lack of its lubricant effects results in considerable pain and inflammation for the horse. The Company has been selling different formulations of sodium hyaluronate in Canada (I.A. only), Australia and New Zealand - as Enhance(®)( )- since 2001/02. Both Enhance(®) and NexHA(TM) are produced with a sodium hyaluronate solution that is obtained from a selective fermentation source using a manufacturing process that is free from thermal degrading effects. "Enhance® has been a very successful product for us in Australia, and we look forward to making this new formulation - NexHA(TM) - available to our Canadian equine veterinary customers, followed by veterinarians in other global jurisdictions in the future," said Mr. Andrew Grant, President of Bioniche Animal Health (global). "Whether it's racing, sport or pleasure riding, Bioniche has a broad range of equine products to support the wellness and performance of all horses. Our portfolio includes specialized nutritional supplements, joint care, wound care, immunostimulants and products to assist through the reproduction cycle from pregnancy to a healthy foal." About Bioniche Life Sciences Inc. Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value. Bioniche Animal Health develops, manufactures and markets veterinary biopharmaceutical products worldwide. In North America, it has development, manufacturing and marketing facilities in Belleville, Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington, U.S.A. In Australia, business is conducted from two sites: Sydney, New South Wales, where sales and marketing, customer support and technical service are located; and Armidale, New South Wales, where research, development and manufacturing facilities are located. Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2010. For more information, please visit www.Bioniche.com. Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Bioniche Life Sciences Inc. CONTACT: Jennifer Shea, Vice-President, Communications, Investor &GovernmentRelationsBioniche Life Sciences Inc.Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097Jennifer.Shea@Bioniche.com

Copyright